18 results on '"Marek, Kenneth L"'
Search Results
2. Amyloid PET across the cognitive spectrum in former professional and college American football players: findings from the DIAGNOSE CTE Research Project.
- Author
-
Stern, Robert A., Trujillo-Rodriguez, Diana, Tripodis, Yorghos, Pulukuri, Surya V., Alosco, Michael L., Adler, Charles H., Balcer, Laura J., Bernick, Charles, Baucom, Zachary, Marek, Kenneth L., McClean, Michael D., Johnson, Keith A., McKee, Ann C., Stein, Thor D., Mez, Jesse, Palmisano, Joseph N., Cummings, Jeffrey L., Shenton, Martha E., Reiman, Eric M., and Chen, Kewei
- Subjects
CHRONIC traumatic encephalopathy ,DISEASE risk factors ,CEREBRAL amyloid angiopathy ,HEAD injuries ,AMYLOID plaque ,FOOTBALL ,CONTACT sports ,MILD cognitive impairment ,MONTREAL Cognitive Assessment - Abstract
Background: Exposure to repetitive head impacts (RHI) in American football players can lead to cognitive impairment and dementia due to neurodegenerative disease, particularly chronic traumatic encephalopathy (CTE). The pathognomonic lesion of CTE consists of perivascular aggregates of hyper-phosphorylated tau in neurons at the depths of cortical sulci. However, it is unclear whether exposure to RHI accelerates amyloid-β (Aβ) plaque formation and increases the risk for Alzheimer's disease (AD). Although the Aβ neuritic plaques characteristic of AD are observed in a minority of later-stage CTE cases, diffuse plaques are more common. This study examined whether former professional and college American football players, including those with cognitive impairment and dementia, have elevated neuritic Aβ plaque density, as measured by florbetapir PET. Regardless of cognitive and functional status, elevated levels of florbetapir uptake were not expected. Methods: We examined 237 men ages 45–74, including 119 former professional (PRO) and 60 former college (COL) football players, with and without cognitive impairment and dementia, and 58 same-age men without a history of contact sports or TBI (unexposed; UE) and who denied cognitive or behavioral symptoms at telephone screening. Former players were categorized into four diagnostic groups: normal cognition, subjective memory impairment, mild cognitive impairment, and dementia. Positive florbetapir PET was defined by cortical-cerebellar average SUVR of ≥ 1.10. Multivariable linear regression and analysis of covariance (ANCOVA) compared florbetapir average SUVR across diagnostic and exposure groups. Multivariable logistic regression compared florbetapir positivity. Race, education, age, and APOE4 were covariates. Results: There were no diagnostic group differences either in florbetapir average SUVR or the proportion of elevated florbetapir uptake. Average SUVR means also did not differ between exposure groups: PRO-COL (p = 0.94, 95% C.I. = [− 0.033, 0.025]), PRO-UE (p = 0.40, 95% C.I. = [− 0.010, 0.029]), COL-UE (p = 0.36, 95% CI = [0.0004, 0.039]). Florbetapir was not significantly associated with years of football exposure, cognition, or daily functioning. Conclusions: Cognitive impairment in former American football players is not associated with PET imaging of neuritic Aβ plaque deposition. These findings are inconsistent with a neuropathological diagnosis of AD in individuals with substantial RHI exposure and have both clinical and medico-legal implications. Trial registration: NCT02798185. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Associations between near end-of-life flortaucipir PET and postmortem CTE-related tau neuropathology in six former American football players.
- Author
-
Alosco, Michael L., Su, Yi, Stein, Thor D., Protas, Hillary, Cherry, Jonathan D., Adler, Charles H., Balcer, Laura J., Bernick, Charles, Pulukuri, Surya Vamsi, Abdolmohammadi, Bobak, Coleman, Michael J., Palmisano, Joseph N., Tripodis, Yorghos, Mez, Jesse, Rabinovici, Gil D., Marek, Kenneth L., Beach, Thomas G., Johnson, Keith A., Huber, Bertrand Russell, and Koerte, Inga
- Subjects
NEUROLOGICAL disorders ,FOOTBALL players ,BIOMARKERS ,CHRONIC traumatic encephalopathy ,AUTOPSY - Abstract
Purpose: Flourine-18-flortaucipir tau positron emission tomography (PET) was developed for the detection for Alzheimer's disease. Human imaging studies have begun to investigate its use in chronic traumatic encephalopathy (CTE). Flortaucipir-PET to autopsy correlation studies in CTE are needed for diagnostic validation. We examined the association between end-of-life flortaucipir PET and postmortem neuropathological measurements of CTE-related tau in six former American football players. Methods: Three former National Football League players and three former college football players who were part of the DIAGNOSE CTE Research Project died and agreed to have their brains donated. The six players had flortaucipir (tau) and florbetapir (amyloid) PET prior to death. All brains from the deceased participants were neuropathologically evaluated for the presence of CTE. On average, the participants were 59.0 (SD = 9.32) years of age at time of PET. PET scans were acquired 20.33 (SD = 13.08) months before their death. Using Spearman correlation analyses, we compared flortaucipir standard uptake value ratios (SUVRs) to digital slide-based AT8 phosphorylated tau (p-tau) density in a priori selected composite cortical, composite limbic, and thalamic regions-of-interest (ROIs). Results: Four brain donors had autopsy-confirmed CTE, all with high stage disease (n = 3 stage III, n = 1 stage IV). Three of these four met criteria for the clinical syndrome of CTE, known as traumatic encephalopathy syndrome (TES). Two did not have CTE at autopsy and one of these met criteria for TES. Concomitant pathology was only present in one of the non-CTE cases (Lewy body) and one of the CTE cases (motor neuron disease). There was a strong association between flortaucipir SUVRs and p-tau density in the composite cortical (ρ = 0.71) and limbic (ρ = 0.77) ROIs. Although there was a strong association in the thalamic ROI (ρ = 0.83), this is a region with known off-target binding. SUVRs were modest and CTE and non-CTE cases had overlapping SUVRs and discordant p-tau density for some regions. Conclusions: Flortaucipir-PET could be useful for detecting high stage CTE neuropathology, but specificity to CTE p-tau is uncertain. Off-target flortaucipir binding in the hippocampus and thalamus complicates interpretation of these associations. In vivo biomarkers that can detect the specific p-tau of CTE across the disease continuum are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project.
- Author
-
Alosco, Michael L., Mariani, Megan L., Adler, Charles H., Balcer, Laura J., Bernick, Charles, Au, Rhoda, Banks, Sarah J., Barr, William B., Bouix, Sylvain, Cantu, Robert C., Coleman, Michael J., Dodick, David W., Farrer, Lindsay A., Geda, Yonas E., Katz, Douglas I., Koerte, Inga K., Kowall, Neil W., Lin, Alexander P., Marcus, Daniel S., and Marek, Kenneth L.
- Subjects
CHRONIC traumatic encephalopathy ,DIAGNOSIS ,MAGNETIC resonance imaging ,MEDICAL research ,POSITRON emission tomography ,NEUROLOGIC examination ,PSYCHIATRIC epidemiology - Abstract
Background: Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that has been neuropathologically diagnosed in brain donors exposed to repetitive head impacts, including boxers and American football, soccer, ice hockey, and rugby players. CTE cannot yet be diagnosed during life. In December 2015, the National Institute of Neurological Disorders and Stroke awarded a seven-year grant (U01NS093334) to fund the "Diagnostics, Imaging, and Genetics Network for the Objective Study and Evaluation of Chronic Traumatic Encephalopathy (DIAGNOSE CTE) Research Project." The objectives of this multicenter project are to: develop in vivo fluid and neuroimaging biomarkers for CTE; characterize its clinical presentation; refine and validate clinical research diagnostic criteria (i.e., traumatic encephalopathy syndrome [TES]); examine repetitive head impact exposure, genetic, and other risk factors; and provide shared resources of anonymized data and biological samples to the research community. In this paper, we provide a detailed overview of the rationale, design, and methods for the DIAGNOSE CTE Research Project. Methods: The targeted sample and sample size was 240 male participants, ages 45–74, including 120 former professional football players, 60 former collegiate football players, and 60 asymptomatic participants without a history of head trauma or participation in organized contact sports. Participants were evaluated at one of four U.S. sites and underwent the following baseline procedures: neurological and neuropsychological examinations; tau and amyloid positron emission tomography; magnetic resonance imaging and spectroscopy; lumbar puncture; blood and saliva collection; and standardized self-report measures of neuropsychiatric, cognitive, and daily functioning. Study partners completed similar informant-report measures. Follow-up evaluations were intended to be in-person and at 3 years post-baseline. Multidisciplinary diagnostic consensus conferences are held, and the reliability and validity of TES diagnostic criteria are examined. Results: Participant enrollment and all baseline evaluations were completed in February 2020. Three-year follow-up evaluations began in October 2019. However, in-person evaluation ceased with the COVID-19 pandemic, and resumed as remote, 4-year follow-up evaluations (including telephone-, online-, and videoconference-based cognitive, neuropsychiatric, and neurologic examinations, as well as in-home blood draw) in February 2021. Conclusions: Findings from the DIAGNOSE CTE Research Project should facilitate detection and diagnosis of CTE during life, and thereby accelerate research on risk factors, mechanisms, epidemiology, treatment, and prevention of CTE. Trial registration: NCT02798185 [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. The Effect of the COVID-19 Pandemic on People with Parkinson's Disease.
- Author
-
Brown, Ethan G., Chahine, Lana M., Goldman, Samuel M., Korell, Monica, Mann, Emerald, Kinel, Daniel R., Arnedo, Vanessa, Marek, Kenneth L., and Tanner, Caroline M.
- Subjects
COVID-19 pandemic ,PARKINSON'S disease ,COVID-19 ,LIVING alone - Abstract
Background: The effect of the COVID-19 pandemic on people with Parkinson's disease (PD) is poorly understood. Objective: To rapidly identify areas of need and improve care in people with PD during the COVID-19 pandemic, we deployed a survey to assess COVID-19 symptoms and the pandemic's effect among those with and without COVID-19. Methods: People with and without PD participating in the online study Fox Insight (FI) were invited to complete a survey between April 23 and May 23, 2020. Among people reporting COVID-19 diagnoses, we compared symptoms and outcomes in people with and without PD. Among people not reporting COVID-19, we assessed access to healthcare and services and PD symptoms. Results: 7,209/9,762 active FI users responded (approximately 74% response rate), 5,429 people with PD and 1,452 without PD. COVID-19 diagnoses were reported by 51 people with and 26 without PD. Complications were more frequent in people with longer PD duration. People with PD and COVID-19 experienced new or worsening motor (63%) and nonmotor (75%) symptoms. People with PD not diagnosed with COVID-19 reported disrupted medical care (64%), exercise (21%), and social activities (57%), and worsened motor (43%) and non-motor (52%) symptoms. Disruptions were more common for those living alone, with lower income and non-White race. Conclusions: The COVID-19 pandemic is associated with wide-ranging effects on people with PD, and certain groups may be at particular risk. FI provides a rapid, patient-centered means to assess these effects and identify needs that can be used to improve the health of people with PD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging.
- Author
-
Russell, David S., Jennings, Danna L., Barret, Olivier, Tamagnan, Gilles D., Carroll, Vincent M., Caillé, Fabien, Alagille, David, Morley, Thomas J., Papin, Caroline, Seibyl, John P., and Marek, Kenneth L.
- Published
- 2016
- Full Text
- View/download PDF
7. The Phosphodiesterase 10 Positron Emission Tomography Tracer, [18F]MNI-659, as a Novel Biomarker for Early Huntington Disease.
- Author
-
Russell, David S., Barret, Olivier, Jennings, Danna L., Friedman, Joseph H., Tamagnan, Gilles D., Thomae, David, Alagille, David, Morley, Thomas J., Papin, Caroline, Papapetropoulos, Spyridon, Waterhouse, Rikki N., Seibyl, John P., and Marek, Kenneth L.
- Published
- 2014
- Full Text
- View/download PDF
8. Kinetic Modeling, Test--Retest, and Dosimetry of 123I-MNI-420 in Humans.
- Author
-
Tavares, Adriana Alexandre S., Batis, Jeffery C., Papin, Caroline, Jennings, Danna, Alagille, David, Russell, David S., Vala, Christine, Hsiaoju Lee, Baldwin, Ronald M., Zubal, I. George, Marek, Kenneth L., Seibyl, John P., Barret, Olivier, and Tamagnan, Gilles D.
- Published
- 2013
- Full Text
- View/download PDF
9. Estimating the half-lives of PCB congeners in former capacitor workers measured over a 28-year interval.
- Author
-
Seegal, Richard F, Fitzgerald, Edward F, Hills, Elaine A, Wolff, Mary S, Haase, Richard F, Todd, Andrew C, Parsons, Patrick, Molho, Eric S, Higgins, Donald S, Factor, Stewart A, Marek, Kenneth L, Seibyl, John P, Jennings, Danna L, and Mccaffrey, Robert J
- Subjects
HAZARDOUS substance exposure ,POLYCHLORINATED biphenyls ,HALF-life (Nuclear physics) ,SERUM ,TOXICOLOGICAL chemistry ,EPIDEMIOLOGY ,OCCUPATIONAL diseases - Abstract
To date, most estimates of the half-life of polychlorinated biphenyls (PCBs) in humans have been based on relatively short follow-up periods. To address this issue, we determined the half-lives of PCB congeners of occupational origin in the serum of former capacitor workers as part of a study conducted in 2003-2006 - approximately 28 years after their last occupational exposure. A total of 241 persons from a source population of 6798 former capacitor workers were interviewed and asked to donate a blood sample for serum PCB congener analysis. A subgroup of 45 participants also had serum archived from 1976 and reanalyzed for the same 27 PCB congeners by the same laboratory. Our estimates of the half-lives of the congeners among these 45 persons were longer than those reported by Wolff et al. (1992), due primarily to the much longer interval between exposure and determination of serum PCB concentrations. Half-lives were significantly greater for the heavy versus light occupational congeners, for women versus men and for those with low versus high initial exposure. Current serum total PCB concentrations, expressed as the geometric mean of wet weight data, averaged 6.7 ng/g for the entire 241-person cohort, which represents a 10-fold decrease from values reported in the late 1970s, but is still nearly twice the average for persons of similar age residing in the same area, but without occupational exposure. In addition, current serum PCB concentrations remained significantly and positively associated with earlier occupational exposure, but were not associated with fresh water fish consumption. In general, the results support a consistent and long-duration trend of increased PCB body burden in this cohort of former capacitor workers compared with non-occupationally exposed individuals. The results may aid in further understanding the toxicological/epidemiological consequences of exposure to PCBs in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
10. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
- Author
-
Stern, Matthew B., Marek, Kenneth L., Friedman, Joseph, Hauser, Robert A., LeWitt, Peter A., Tarsy, Daniel, and Olanow, C. Warren
- Abstract
Rasagiline ( N-propargyl-1( R)-aminoindan) mesylate is a potent, selective, and irreversible monoamine oxidase-B inhibitor. This study was designed to evaluate the safety, tolerability, and preliminary efficacy of rasagiline monotherapy in early Parkinson's disease (PD) patients not receiving levodopa. The study was performed as a multicenter, parallel-group, double-blind, randomized, placebo-controlled, 10-week study. Fifty-six PD patients were randomly assigned to rasagiline mesylate 1, 2, or 4 mg once daily, or placebo. A 3-week dose-escalation period was followed by a 7-week maintenance phase. At week 10, the mean (±SE) changes from baseline in total Unified Parkinson's Disease Rating Scale (UPDRS) score were −1.8 (±1.3), −3.6 (±1.7), −3.6 (±1.2), and −0.5 (±0.8) in the rasagiline 1, 2, and 4 mg/day and placebo groups, respectively. Analysis of responders showed that 28% of patients (12 of 43) receiving rasagiline had an improvement in total UPDRS score of greater than 30%, compared with none of the patients receiving placebo ( P < 0.05, Fisher's exact test). The frequency and types of adverse events reported by rasagiline-treated and placebo-treated patients were similar. These results suggest that rasagiline monotherapy is well tolerated and efficacious in early PD. © 2004 Movement Disorder Society [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
11. The Natural History of the Syndrome of Primary Progressive Freezing Gait.
- Author
-
Factor, Stewart A., Jennings, Danna L., Molho, Eric S., and Marek, Kenneth L.
- Subjects
GAIT disorders ,TOMOGRAPHY ,MAGNETIC resonance imaging - Abstract
Background: Primary progressive freezing gait disorder is considered to be a distinct clinical entity that manifests predominantly as a progressive freezing gait disorder without accompanying abnormalities. However, confusion remains about its clinical presentation, natural history, and classification. Objective: To examine the natural history, clinical and brain imaging characteristics, and response to dopaminergic medications of primary progressive freezing gait (PPFG) disorder. Design/Methods: Review of medical records, videotape examinations, and computed tomographic and magnetic resonance imaging of the brain and results of neurological evaluations, including the Unified Parkinson's Disease Rating Scale, in patients with PPFG. Results: Thirty patients (16 male) were diagnosed as having PPFG (mean age at onset, 72.2 years; mean duration of disease, 5 years). Gait disorder was the initial complaint in 27 patients. Freezing gait was the initial manifestation in 18 and was present within the first year in 27. Natural history included 25 patients falling within 3 years of onset, 20 experiencing retropulsion within 4 years, and 16 requiring wheelchairs by 5 years. On neurological examination, bradykinesia was present in 29 patients, muscle rigidity in 15, and postural tremor in 11. Other features included speech abnormalities in 10, hyperreflexia without clonus in 17, and dementia in 8. Extraocular movement abnormalities and dysphagia were rare. All 30 patients were treated with levodopa with minimal effect. Eighteen were treated with a dopamine agonist with no notable effect. Of the 23 patients with magnetic resonance imaging scans, results were normal in 9 and included minor nonspecific changes in 14. The computed tomographic scans obtained in 12 patients showed similar results. One patient underwent fluorine F ([SUP18]SF) labeled deoxyglucose positron emission tomography, which showed mild reduction in medial frontal glucose metabolism. Conclusions: Primary... [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
12. [123I]β-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy.
- Author
-
Varrone, Andrea, Marek, Kenneth L., Jennings, Danna, Innis, Robert B., and Seibyl, John P.
- Published
- 2001
- Full Text
- View/download PDF
13. Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.
- Author
-
Innis, Robert B., Marek, Kenneth L., Sheff, Kim, Zoghbi, Sami, Castronuovo, Joseph, Feigin, Andrew, Seibyl, John P., Innis, R B, Marek, K L, Sheff, K, Zoghbi, S, Castronuovo, J, Feigin, A, and Seibyl, J P
- Published
- 1999
- Full Text
- View/download PDF
14. Randomized, Placebo-Controlled Study of Tolcapone in Patients With Fluctuating Parkinson Disease Treated With Levodopa-Carbidopa.
- Author
-
Adler, Charles H., Singer, Carlos, O'Brien, Christopher, Hauser, Robert A., Lew, Mark F., Marek, Kenneth L., Dorflinger, Ernest, Pedder, Simon, Deptula, Dennis, and Yoo, Kisook
- Subjects
METHYLTRANSFERASES ,DOPA ,PARKINSON'S disease patients ,CHEMICAL inhibitors ,BIOCHEMICAL mechanism of action ,THERAPEUTICS - Abstract
Objective: To assess the efficacy and tolerability of the catechol-O-methyltransferase inhibitor tolcapone in reducing "off/on" fluctuations in levodopa-treated parkinsonian patients. Design: A randomized, double-blind, placebo-controlled, parallel-group study. Setting: Fifteen Parkinson disease clinics. Patients: Two hundred fifteen referred outpatients with Parkinson disease who showed predictable end-of-dose motor fluctuations that were not controlled by a stable levodopa-carbidopa (Sinemet) regimen of at least 4 weeks' duration. Interventions: In addition to their usual levodopa-carbidopa regimen, patients received placebo or tolcapone, 100 or 200 mg, 3 times daily orally for 6 weeks. Primary Outcome Measure: Change in daily off/on time. Results: Tolcapone, 100 and 200 mg 3 times daily, reduced off time by 2.0 and 2.5 hours per day, respectively, and increased on time by 2.1 and 2.3 hours per day, respectively (P<.001 vs placebo). Investigators' global measures of disease severity indicated that significantly more tolcapone-treated patients had reduced wearing off and symptom severity (P<.001 vs placebo). No significant change in quality-of-life measures occurred. Clinical improvements occurred despite a reduction in total daily levodopa dose of 185.5 mg (23%) in the tolcapone, 100 mg 3 times daily, group and 251.5 mg (29%) in the 200 mg 3 times daily group. Principal adverse events (mainly dyskinesia and nausea) were levodopa related, were not treatment limiting, and were seldom reported as reasons for withdrawal. The frequency of withdrawals because of adverse events was similar in all groups (3% to 7%). Conclusions: Tolcapone was well tolerated and substantially increased on time and reduced off time in patients with fluctuating Parkinson disease. Additionally, levodopa requirements were significantly decreased. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
15. Neural Transplantation for Neurodegenerative Diseases: Past, Present, and Future.
- Author
-
REDMOND, D. EUGENE, ROTH, ROBERT H., SPENCER, DENNIS D., NAFTOLIN, FREDERICK, LERANTH, CSABA, ROBBINS, RICHARD J., MAREK, KENNETH L., ELSWORTH, JOHN D., SASS, KIMBERLEE J., TAYLOR, JANE R., and SLADEK, JOHN R.
- Published
- 1993
- Full Text
- View/download PDF
16. Unilateral Transplantation of Human Fetal Mesencephalic Tissue Into the Caudate Nucleus of Patients With Parkinson's Disease.
- Author
-
SPENCER, DENNIS D., ROBBINS, RICHARD J., NAFTOLIN, FREDERICK, MAREK, KENNETH L., VOLLMER, TIMOTHY, LERANTH, CSABA, ROTH, ROBERT H., PRICE, LAWRENCE H., GJEDDE, ALBERT, BUNNEY, BENJAMIN S., SASS, KIMBERLEE J., ELSWORTH, JOHN D., KIER, E LEON, MAKUCH, ROBERT, HOFFER, PAUL B., and REDMOND JR., D EUGENE
- Published
- 1993
- Full Text
- View/download PDF
17. Serotonergic dysfunction in depression associated with Parkinson's disease.
- Author
-
McCance-Katz, Elinore F., Marek, Kenneth L., Price, Lawrence H., McCance-Katz, E F, Marek, K L, and Price, L H
- Published
- 1992
- Full Text
- View/download PDF
18. Serotonin, depression, and PD.
- Author
-
McCance-Katz, Elinore F., Marek, Kenneth L., and Price, Lawrence H.
- Published
- 1993
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.